The abstract is read at the publisher; the summary is JClub's.
A phase 3 trial found that a single dose of lonvoguran ziclumeran, an in vivo CRISPR-Cas9 therapy targeting KLKB1, significantly reduced hereditary angioedema attack rates.
- Why it matters: Hereditary angioedema is a bradykinin-mediated genetic disorder, and while long-term prophylaxis is increasingly effective, durable control still depends on better targeted options.
- What they did: The study tested lonvoguran ziclumeran as a one-time in vivo CRISPR-Cas9 treatment aimed at KLKB1 in a phase 3 clinical trial.
- The result: The significant reduction in attack rates supports this strategy as highly promising, while the trial’s success also highlights the need for further investigation into key unanswered questions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.